ALMS Key Statistics, Chart & Performance
The current stock price of ALMS is 11.16 USD. In the past month the price increased by 136.44%. In the past year, price increased by 33.02%.
ALMS Latest News, Press Relases and Analysis
ALMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.37 | 943.10B | ||
| JNJ | JOHNSON & JOHNSON | 19.42 | 485.76B | ||
| MRK | MERCK & CO. INC. | 11.23 | 245.55B | ||
| PFE | PFIZER INC | 8.05 | 146.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.88 | 105.19B | ||
| ZTS | ZOETIS INC | 18.64 | 52.07B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.41 | 22.32B | ||
| VTRS | VIATRIS INC | 4.76 | 12.77B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.59 | 10.78B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.3 | 8.73B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.44B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About ALMS
Company Profile
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 250 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Company Info
ALUMIS INC
280 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 250
Phone: 16502316625
ALUMIS INC / ALMS FAQ
Can you describe the business of ALUMIS INC?
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 250 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
What is the stock price of ALUMIS INC today?
The current stock price of ALMS is 11.16 USD. The price increased by 0.36% in the last trading session.
Does ALUMIS INC pay dividends?
ALMS does not pay a dividend.
What is the ChartMill rating of ALUMIS INC stock?
ALMS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for ALUMIS INC?
ALUMIS INC (ALMS) currently has 250 employees.
What is the Short Interest ratio of ALUMIS INC (ALMS) stock?
The outstanding short interest for ALUMIS INC (ALMS) is 5.61% of its float.
ALMS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALMS. When comparing the yearly performance of all stocks, ALMS is one of the better performing stocks in the market, outperforming 96.84% of all stocks.
ALMS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALMS. While ALMS has a great health rating, there are worries on its profitability.
ALMS Financial Highlights
Over the last trailing twelve months ALMS reported a non-GAAP Earnings per Share(EPS) of -5.46. The EPS decreased by -80.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.24% | ||
| ROE | -46.88% | ||
| Debt/Equity | 0 |
ALMS Forecast & Estimates
14 analysts have analysed ALMS and the average price target is 19.38 USD. This implies a price increase of 73.66% is expected in the next year compared to the current price of 11.16.